Liposomes Patents (Class 424/450)
-
Patent number: 11208468Abstract: Compositions and methods for treating melanoma are provided. Compositions include BRAFV600E-based peptides, alone or admixed with T helper peptides. Other compositions include nucleic acid sequences encoding the BRAFV600E-based peptides, alone or admixed with nucleic acid sequences T helper peptides. Dendritic cells pretreated with the BRAFV600E-based peptides, alone or admixed with T helper peptides, are also provided. These compositions are useful to treat melanoma, optionally co-administered with antibodies to checkpoint inhibitors or molecules that mimic the action of such antibodies.Type: GrantFiled: February 16, 2017Date of Patent: December 28, 2021Assignee: The Wistar Institute of Anatomy and BiologyInventors: Rajasekharan Somasundaram, Meenhard Herlyn, Dorothee Herlyn
-
Patent number: 11208405Abstract: The invention provides compounds of the formula (3): or a pharmaceutically acceptable salt or tautomer thereof, wherein: Z is a 5-membered heteroaryl ring containing one or two nitrogen ring members and optionally one further heteroatom ring member selected from N and O; ring X is a benzene or pyridine ring; ring Y is a benzene, pyridine, thiophene or furan ring; Ar1 is an optionally substituted benzene, pyridine, thiophene or furan ring; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected from various substituents: R2 is selected from hydrogen and a C1-4 hydrocarbon group; R3 is selected from hydrogen and a C1-4 hydrocarbon group; R4 is selected from various substituents; R5 is selected from various substituents; Ar2 is an optionally substituted phenyl, pyridyl or pyridone group; R6 is a group Q1-Ra—Rb; Q1 is absent or is a C1-3 saturated hydrocarbon linker; Ra is selected from O; C(O); C(O)O; CONRc; N(Rc)CO; N(Rc)CONRc, NRc; and SO2NRc; Rb is selected from hydrogen and various substituents;Type: GrantFiled: April 27, 2018Date of Patent: December 28, 2021Assignee: SENTINEL ONCOLOGY LIMITEDInventors: Robert George Boyle, David Winter Walker, Richard Justin Boyce
-
Patent number: 11207428Abstract: Disclosed herein are nanoconstructs comprising a nanoparticle, coated with additional agents such as cationic polymers, stabilizers, targeting molecules, labels, oligonucleotides and small molecules. These constructs may be used to deliver compounds to treat solid tumors and to diagnose cancer and other diseases. Further disclosed are methods of making such compounds and use of such compounds to treat or diagnose human disease.Type: GrantFiled: February 10, 2017Date of Patent: December 28, 2021Assignees: Oregon Health & Science University, PDX Pharmaceuticals, Inc.Inventors: Wassana Yantasee, Worapol Ngamcherdtrakul, Jingga Morry, David Castro, Joe Gray
-
Patent number: 11202820Abstract: The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions. In the preferred embodiment, the protein nanocage is composed of Bacillus stearothermophilus E2 protein of pyruvate dehydrogenase multi-enzyme complex (E2), with a skin penetrating and cell permeating SPACE moiety, and a melanocyte-targeting moiety of alpha melanocyte stimulating hormone.Type: GrantFiled: September 25, 2015Date of Patent: December 21, 2021Assignees: NANYANG TECHNOLOGICAL UNIVERSITY, NATIONAL SKIN CENTER (S) PTE LTDInventors: Sierin Lim, Sathyamoorthy Bhaskar, Steven Thng, Ambili Kuniyil, Sarker Mridul
-
Patent number: 11202860Abstract: A drug delivery system includes a substrate, an integrated sensor disposed on the substrate, a drug delivery element disposed on the substrate, and a control unit coupled to the integrated sensor and the drug delivery element. The integrated sensor includes first and second electrodes disposed on a first surface of the substrate. The drug delivery element includes a reservoir disposed on the first surface of the substrate, a thermally active polymer enclosing the reservoir, and a heating coil disposed over the thermally active polymer. The control unit is configured to measure a biological parameter by measuring a voltage difference between the first and second electrodes of the integrated sensor, and to apply a trigger signal to the heating coil of the drug delivery element responsive to the measured biological parameter indicating a designated condition to heat up the thermally active polymer to selectively release a drug from the reservoir.Type: GrantFiled: June 6, 2018Date of Patent: December 21, 2021Assignee: International Business Machines CorporationInventors: Qing Cao, Shu-Jen Han, Jianshi Tang, Bharat Kumar
-
Patent number: 11191774Abstract: Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.Type: GrantFiled: November 23, 2016Date of Patent: December 7, 2021Assignee: The Regents of the University of CaliforniaInventors: Samir Mitragotri, Marta Broto, Kathryn M. Camacho, Stefano Menegatti
-
Patent number: 11191848Abstract: The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.Type: GrantFiled: July 8, 2019Date of Patent: December 7, 2021Assignee: Vascular Biogenics Ltd.Inventors: Andrea Rachel Leubitz, Naamit Sher, Erez Feige, Eyal Breitbart
-
Patent number: 11191288Abstract: The present invention relates to the field of reduction of methane emission in ruminants. Particularly, it relates to the use of a feed composition or a feed additive comprising at least one fatty acid containing at least 5 carbon atoms and at least one organic molecule substituted at any position with at least one nitrooxy group, for reducing the production of methane emanating from the digestive activities of ruminants, and/or to improve the ruminant performance.Type: GrantFiled: February 9, 2018Date of Patent: December 7, 2021Assignee: DSM IP ASSETS B.V.Inventors: Stephane Duval, Maik Kindermann
-
Patent number: 11185595Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: June 7, 2021Date of Patent: November 30, 2021Assignee: Translate Bio, Inc.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 11185096Abstract: A consumable composition may include naringenin at concentrations suitable to improve certain characteristics of the composition. Naringenin may, for example, be added to a composition or included in a sweetening composition that may be added therein to adjust sweetness attributes. For example, beverages that include one or more steviol glycosides may typically be deficient in upfront sweetness, and naringenin may be added therein to improve the temporal profile of sweetness delivery.Type: GrantFiled: March 6, 2019Date of Patent: November 30, 2021Assignee: DR PEPPER/SEVEN UP, INC.Inventors: Stacey K. Walton, Gino E. Olcese
-
Patent number: 11179335Abstract: Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.Type: GrantFiled: November 21, 2019Date of Patent: November 23, 2021Assignee: VERILY LIFE SCIENCES LLCInventors: Kimberly Kam, Zhan Wang, Stephen Morton, Nicole Peck
-
Compositions and method for administering PPARgamma agonists, surfactant peptides and phosopholipids
Patent number: 11179446Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.Type: GrantFiled: March 6, 2017Date of Patent: November 23, 2021Assignee: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR—UCLA MEDICAL CENTERInventors: Virender K. Rehan, John S. Torday, Frans J. Walther, Alan J. Waring, Larry M. Gordon -
Patent number: 11179336Abstract: Embodiments of the present application relate to commercial manufacturing processes for making bupivacaine multivesicular liposomes (MVLs) using independently operating dual tangential flow filtration modules.Type: GrantFiled: May 13, 2021Date of Patent: November 23, 2021Assignee: Pacira Pharmaceuticals, Inc.Inventors: Jeffrey S. Hall, David J. Turnbull, John J. Grigsby, Jr., Soroush M. Ardekani, Paige N. Davis, Louie D. Garcia, Stephanie M. Kurz, Kathleen D. A. Los
-
Patent number: 11179353Abstract: A composition comprising at least one TCA or SSRI useful in a method for preventing or treating a skin disorder such as radiation dermatitis, and method of preventing, ameliorating, or treating the skin disorder by administering an effective amount of the TCA, e.g., amitriptyline or the SSRI, e.g., sertraline.Type: GrantFiled: September 22, 2020Date of Patent: November 23, 2021Inventors: Reginald L. Hardy, Mitchell Brigell
-
Patent number: 11173119Abstract: A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.Type: GrantFiled: December 12, 2019Date of Patent: November 16, 2021Assignee: Yale UniversityInventors: Tarek M. Fahmy, Eric Stern, Richard A. Flavell, Jason Park, Alyssa Siefert, Stephen H. Wrzesinski
-
Patent number: 11173178Abstract: The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of the liposome. Thus, the liposomes of the invention may e.g. be used in relation to cancer therapy. Another aspect of the invention is a liposomal formulation comprising the liposome of the invention. Still another aspect is a method of producing a liposomal formulation of the invention.Type: GrantFiled: February 10, 2020Date of Patent: November 16, 2021Assignee: LiPlasome Pharma ApSInventors: Anders Falk Vikbjerg, Sune Allan Petersen, Fredrik Melander, Jonas Rosager Henriksen, Kent Jørgensen
-
Patent number: 11166909Abstract: The invention pertains to liposomes containing an oil-in-water emulsion of a selected combination of at least ten different essential plant oils produced with phospholipids found in human membranes and methods for treating respiratory diseases, disorders or conditions by administering the liposomes into the nose and respiratory system.Type: GrantFiled: April 20, 2021Date of Patent: November 9, 2021Assignee: King Abdulaziz UniversityInventors: Taha Kumosani, Elie Barbour, Werner Krull, Soonham Yaghmoor
-
Patent number: 11154534Abstract: An object of the present invention is to provide a lipid particle composition containing panobinostat or a salt thereof and exhibiting a high bone marrow-targeting capability, and a pharmaceutical composition including the lipid particle composition. According to the present invention, provided is a lipid particle composition containing panobinostat or a salt thereof, in which a lipid particle contains a phospholipid and cholesterol.Type: GrantFiled: June 21, 2019Date of Patent: October 26, 2021Assignee: FUJIFILM CorporationInventors: Yuta Yoshino, Hayato Ogura, Mikinaga Mori, Taisuke Endo, Kentaro Numajiri, Ritsuko Hori
-
Patent number: 11135309Abstract: The present invention provides a nanoparticle including at least one poly(vinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.Type: GrantFiled: August 15, 2016Date of Patent: October 5, 2021Assignee: The Regents of the University of CaliforniaInventors: Kit S. Lam, Yuanpei Li, Kai Xiao, Caihong Feng
-
Patent number: 11123295Abstract: The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.Type: GrantFiled: July 12, 2017Date of Patent: September 21, 2021Assignee: MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.Inventors: Raphael J. Mannino, Ruying Lu, Doug F. Kling
-
Patent number: 11123291Abstract: Provided is a method of encapsulation, the method including: providing a first mixture; applying heat to the first mixture until the first mixture reaches a first temperature; providing a second mixture; applying heat to the second mixture until the second mixture reaches a second temperature; mixing the first mixture with the second mixture to obtain a third mixture; providing a fourth mixture; applying heat to the fourth mixture until the fourth mixture reaches a third temperature; mixing the third mixture with the fourth mixture to obtain a fifth mixture.Type: GrantFiled: September 14, 2020Date of Patent: September 21, 2021Assignee: Nulixir Inc.Inventor: Ehsan Moaseri
-
Patent number: 11123294Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.Type: GrantFiled: September 12, 2019Date of Patent: September 21, 2021Assignee: Exicure Operating CompanyInventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
-
Patent number: 11123292Abstract: A pharmacologically acceptable emulsion of biocompatible solvent microdroplets is provided for treating atherosclerosis, heart disease and stroke. Intravenous administration of the biocompatible solvent microdroplets enables the microdroplets to bind and dissolve free cholesterol, cholesterol esters or other fatty compounds within the plaque. A high level of selectivity is ensured from energy principals, by designing the microdroplets to have a low interfacial surface energy when binding to free cholesterol or cholesterol esters in arterial plaque and a high interfacial surface energy when coming into contact with blood cells or endothelial cells along the walls of blood vessels. A review of many compounds which may form the basis of the biocompatible solvent from which the microdroplets are fabricated, as well as their solubility parameters are provided.Type: GrantFiled: August 31, 2017Date of Patent: September 21, 2021Inventor: Catherine Beaudin
-
Patent number: 11116765Abstract: Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: GrantFiled: June 26, 2020Date of Patent: September 14, 2021Assignee: GRIFOLS, S.A.Inventors: Igor Gonda, James Blanchard, David C. Cipolla, Luiz Eduardo Moreira Bermudez
-
Patent number: 11116561Abstract: Devices, agents, and associated methods for selective modulation of renal nerves by localized delivery of neural ablative substances are disclosed herein. One aspect of the present technology is directed to a method for delivering a neuromodulatory agent (e.g., capsaicin) via a catheter to a kidney of the patient. The neuromodulatory agent selectively neuromodulates afferent renal nerves in a patient compared efferent renal nerves of the patient. The method can also include removing the catheter from the patient after delivering the neuromodulatory agent to conclude the procedure.Type: GrantFiled: January 17, 2019Date of Patent: September 14, 2021Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.Inventor: Robert J. Melder
-
Patent number: 11116726Abstract: A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1? and/or HIF-2? includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.Type: GrantFiled: November 9, 2016Date of Patent: September 14, 2021Assignee: CHILDRENS RESEARCH INSTITUTE, CHILDRENS NATIONAL MEDICAL CENTERInventors: Yang Liu, Yin Wang, Yan Liu, Christopher Bailey, Pan Zheng
-
Patent number: 11111331Abstract: The present application may provide a block copolymer and a use thereof. The present application may provide a block copolymer and a use thereof. The block copolymer of the present application may have excellent self-assembly properties or phase separation characteristics and simultaneously have characteristics capable of changing the self-assembly structure formed once, or provide a block copolymer capable of forming a pattern of phase separation structures in a polymer membrane.Type: GrantFiled: October 17, 2017Date of Patent: September 7, 2021Inventors: No Jin Park, Jin Kon Kim, Chung Ryong Choi, Sung Soo Yoon
-
Patent number: 11104917Abstract: The present disclosure relates generally to promoters derived from the AAV anti-sense strand, their use in the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the promoters. The present disclosure also relates to enhancers derived from the AAV anti-sense strand, their use in increasing the expression of one or more heterologous coding sequences, and isolated polynucleotides, vectors and recombinant viruses comprising the enhancers.Type: GrantFiled: May 4, 2016Date of Patent: August 31, 2021Assignees: CHILDREN'S MEDICAL RESEARCH INSTITUTE, THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD) (INCORPORATING THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN)Inventors: Grant Logan, Ian Alexander, Allison Dane
-
Patent number: 11103490Abstract: Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.Type: GrantFiled: February 6, 2014Date of Patent: August 31, 2021Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Rajeshwar Motheram, Gregory Charles Williams
-
Patent number: 11103583Abstract: The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.Type: GrantFiled: July 2, 2019Date of Patent: August 31, 2021Assignee: Nitto Denko CorporationInventors: Joseph E. Payne, John A. Gaudette, Zheng Hou, Mohammad Ahmadian, Lei Yu, Victor Knopov, Violetta Akopian, Priya Karmali, Richard P. Witte, Neda Safarzadeh, Wenbin Ying, Jun Zhang
-
Patent number: 11098300Abstract: The present invention relates to a method for the preparation of nanoscale nucleic acid-encircled lipid bilayers, the nanoscale nucleic acid-encircled lipid bilayers and their use.Type: GrantFiled: February 21, 2019Date of Patent: August 24, 2021Assignees: TECHNISCHE UNIVERSITÄT DRESDEN, HELMHOLTZ-ZENTRUM DRESDEN—ROSSENDORF E.V.Inventors: Karim Fahmy, Thorsten-Lars Schmidt, Katarina Iric
-
Patent number: 11096900Abstract: A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.Type: GrantFiled: August 5, 2020Date of Patent: August 24, 2021Assignee: The Regents of the University of CaliforniaInventors: Andre E. Nel, Huan Meng, Xiangsheng Liu
-
Patent number: 11098104Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.Type: GrantFiled: November 10, 2017Date of Patent: August 24, 2021Assignee: BEIJING PROTGEN LTD.Inventors: Daifu Zhou, Wenchao Wang, Hui Li, Guodong Chang
-
Patent number: 11096893Abstract: Disclosed herein are glucose-sensitive drug delivery systems including polymeric shell encapsulating an active agent. Upon exposure to a sufficient concentration of glucose, the shell is ruptured, releasing the active agent for absorption.Type: GrantFiled: June 4, 2018Date of Patent: August 24, 2021Assignee: North Carolina State UniversityInventors: Zhen Gu, Jicheng Yu
-
Patent number: 11090276Abstract: The invention relates to a composition comprising A) microcapsules comprising at least one fat-soluble active substance selected from a vitamin K compound or a provitamin or a prodrug of a vitamin K compound embedded in a matrix comprising a hydrocolloid and optionally one or more other matrix components, and B) at least one dietary mineral; as well as uses and products comprising such compositions.Type: GrantFiled: May 5, 2015Date of Patent: August 17, 2021Assignee: BASF SEInventors: Inger Reidun Aukrust, Helena M. Larsson, Thomas Rove
-
Patent number: 11090236Abstract: An antimicrobial eyelid cleanser composition contains: (a) a hypohalous acid; (b) one or more surfactants having a HLB value of 5 to 18; and (c) an aqueous vehicle, the aqueous vehicle comprising: (i) one or more tonicity adjusters; (ii) one or more osmolality adjusters for adjusting an osmolality of the composition; and (iii) one or more pH adjusters for maintaining the pH of the composition at between about 4.5 to about 8.0. The composition can be dispensed in a foam, liquid, spray, mist, gel or lotion form. The composition can facilitate long term eyelid hygiene by removing excess oil, debris and desquamated skin and provide relief for inflammation of the eyes.Type: GrantFiled: May 1, 2019Date of Patent: August 17, 2021Assignee: OCUSOFT, INC.Inventors: Nat Adkins, Jr., Cynthia Barratt, Thomas Mason, Paramita Sarkar
-
Patent number: 11083705Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.Type: GrantFiled: March 31, 2020Date of Patent: August 10, 2021Assignee: Eisai R&D Management Co., Ltd.Inventors: Taro Semba, Yasuhiro Funahashi
-
Patent number: 11085022Abstract: Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.Type: GrantFiled: November 27, 2014Date of Patent: August 10, 2021Assignee: CHINA PHARMACEUTICAL UNIVERSITYInventors: Can Zhang, Jingwei Xue, Zekai Zhao, Lei Zhang, Yajing Wen
-
Patent number: 11083676Abstract: Disclosed is a method of preparing a product composition comprising steps of: Preparing a mixture composition comprising a surfactant and a high melting point fatty compound and benefit agent; Separately preparing an aqueous base composition comprising a surfactant, a high melting point fatty compound, and an aqueous carrier and wherein the aqueous base composition is substantially free of detersive surfactant; Mixing the mixture composition and the aqueous base composition to form a discrete particle of the mixture composition dispersed in the aqueous base composition. Alternatively, the method comprises steps of preparing a discrete particle of the mixture composition; and mixing it with the aqueous composition. The methods of the present invention provide a product composition with at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; improved deposition of benefit agents; and improved visual/aesthetic appearance.Type: GrantFiled: June 14, 2019Date of Patent: August 10, 2021Assignee: The Procter and Gamble CompanyInventors: Junichi Yokogi, XinHao Zhu, Jorge Max Sunkel
-
Patent number: 11083780Abstract: This disclosure relates to methods of using shear-thinning compositions in the treatment of a vascular disorders, cancers, infections, abscesses, and fistulas.Type: GrantFiled: July 20, 2016Date of Patent: August 10, 2021Assignees: The Brigham and Women's Hospital, Inc., The General Hospital CorporationInventors: Ali Khademosseini, Rahmi Oklu
-
Patent number: 11077057Abstract: Provided herein are small unilamellar vesicles with surface-displayed polymer moieties, and methods of use and manufacture thereof. In particular, provided herein are polymer-grafted nanobins, and methods of drug delivery therewith.Type: GrantFiled: January 9, 2020Date of Patent: August 3, 2021Assignee: Northwestern UniversityInventors: Anthony J. Chipre, SonBinh T. Nguyen
-
Patent number: 11077052Abstract: A multi-phase treatment of a respiratory disease in which one treatment is a lysing defense by applying inhibitory agents to respiratory passages. Application may be by nasal irrigant, oral gargling mouthwash, or smelling salt. Another treatment is an immune system suppressing defense by providing a liposome-based countermeasure to excess activity of the host immune system during COVID-19 infection. The liposome increases bio-activity of probiotics, probiotics-produced therapeutic peptides, bio-peptides, and antioxidant level in the blood with a sustained massive dose of antioxidants to counteract excess oxidation produced by excess activity of the host immune system, when administered through oral route.Type: GrantFiled: September 9, 2020Date of Patent: August 3, 2021Inventor: Malireddy S. Reddy
-
Patent number: 11077197Abstract: The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure XXXIII, wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).Type: GrantFiled: June 8, 2017Date of Patent: August 3, 2021Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: Muthiah Manoharan, Muthusamy Jayaraman, Kallanthottathil G. Rajeev, Laxman Eltepu, Steven Ansell, Jianxin Chen
-
Patent number: 11071726Abstract: Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of gastric cancer, including treatment of patients diagnosed with previously untreated gastric cancer. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks.Type: GrantFiled: November 1, 2017Date of Patent: July 27, 2021Inventors: Jonathan Basil Fitzgerald, Ashish Kalra, Shannon Leonard, Stephan Braun, Bin Zhang
-
Patent number: 11059807Abstract: The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).Type: GrantFiled: November 29, 2018Date of Patent: July 13, 2021Assignee: Dicerna Pharmaceuticals, Inc.Inventor: Bob Dale Brown
-
Patent number: 11058620Abstract: Disclosed is a product composition comprising: a discrete particle of a mixture composition, wherein the mixture composition comprises a surfactant and a high melting point fatty compound and a benefit agent; and an aqueous base composition comprising a surfactant, a high melting point fatty compound, and an aqueous carrier, and wherein the aqueous base composition is substantially free of detersive surfactant. The product composition of the present invention provides at least one the followings: more flexibility in the product composition rheology; improved stability in the product composition; improved deposition of benefit agents; and improved visual/aesthetic appearance.Type: GrantFiled: June 14, 2019Date of Patent: July 13, 2021Assignee: The Procter and Gamble CompanyInventors: Junichi Yokogi, XinHao Zhu, Jorge Max Sunkel
-
Patent number: 11052138Abstract: A nucleic acid encoding a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) operatively linked to a signaling domain that polarizes a macrophage to an M1 macrophage; wherein the nucleic acid is operatively linked to a macrophage specific promoter; and wherein the scFv is specific for a human antigen. Monocytes or macrophages comprising such a nucleic acid.Type: GrantFiled: September 5, 2018Date of Patent: July 6, 2021Assignee: Thunder Biotech Inc.Inventors: Kim Leslie O'Neill, Scott Weber
-
Patent number: 11052044Abstract: Described herein, inter alia, are compositions and methods useful for the reconstitution of membrane proteins.Type: GrantFiled: March 1, 2018Date of Patent: July 6, 2021Assignee: The Regents of the University of CaliforniaInventors: Roberto Javier Brea Fernandez, Christian Cole, Neal K. Devaraj, Brent Lyda, Roger Sunahara
-
Patent number: 11045554Abstract: The present invention relates to lipid-coated particles for treating viral infections, including viral encephalitis infections. In particular, an antiviral compound can be disposed within the lipid-coated particle, thereby providing an antiviral carrier. Methods of making and using such carriers are described herein.Type: GrantFiled: June 17, 2019Date of Patent: June 29, 2021Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Oscar Negrete, C. Jeffrey Brinker, Torri Rinker, Annette Estelle LaBauve
-
Patent number: 11046854Abstract: The present invention provides polymer-based slippery liquid-infused porous surfaces (SLIPS) that can prevent adhesion and colonization by fungal and bacterial pathogens and also kill and/or attenuate the colonization and virulence of non-adherent pathogens in surrounding media. The present approach exploits the polymer and liquid oil phases in these slippery materials to sustain the release of small molecules such as a broad-spectrum antimicrobial agent, an antifungal agent, an antibacterial agent, an agent that modulates bacterial or fungal quorum sensing, an agent that attenuates virulence, or a combination thereof. This controlled release approach improves the inherent anti-fouling properties of SLIPS, has the potential to be general in scope, and expands the potential utility of slippery, non-fouling surfaces in both fundamental and applied contexts.Type: GrantFiled: January 10, 2020Date of Patent: June 29, 2021Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Uttam Manna